Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that Laura Shawver, Ph.D., Silverback’s chief executive officer, will present at the following upcoming investor conferences:
- Event: Goldman Sachs West Coast Biotech Bus Tour
Location: Virtual
Date: Tuesday, February 23, 2021
Time: 2:00 PM ET / 11:00 AM PT
- Event: SVB Leerink 10 th Annual Global Healthcare Conference
Location: Virtual
Date: Wednesday, February 24, 2021
Time: 4:20 PM ET / 1:20 PM PT
- Event: Cowen 41 st Annual Healthcare Conference
Location: Virtual
Date: Wednesday, March 3, 2021
Time: 3:20 PM ET / 12:20 PM PT
- Event: H.C. Wainwright Global Life Sciences Conference
Location: Virtual
Date: Tuesday, March 9, 2021
Time: 7:00 AM ET / 4:00 AM PT
The webcast and archived replay of the SVB Leerink, Cowen, and H.C. Wainwright presentations will be available on the Silverback website, www.silverbacktx.com , for 30 days.
About Silverback Therapeutics
Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Silverback’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. Initially, Silverback is creating a new class of targeted immuno-oncology agents that direct a TLR8 agonist myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing. Silverback Therapeutics is located in Seattle, Washington. To learn more, visit www.silverbacktx.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005502/en/
Investor Contact:
Miguel Arcinas
Silverback Therapeutics
(206) 736-7946
ir@silverbacktx.com
Media Contact:
Steve E. Kunszabo
Canale Communications
(619) 849-5392
steve.kunszabo@canalecomm.com